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Abstract 
 
Background  
Pump thrombosis (PT) is a relatively uncommon but serious complication of a left 
ventricular assist device (LVAD). We believe that de-airing of the HeartMate II 
(HMII) with the pump turned on and a clamp across the outflow graft may lead to 
early thrombus formation due to heat generation on the bearings.  
 
Methods 
 
Patients who underwent HMII implantation from November 2012 to February 2016 
were retrospectively reviewed. Patients were separated into two groups depending 
on the timing of removing the clamp from the outflow graft. Patients in Group 1 
underwent de-airing by turning on the pump with the vascular clamp on the outflow 
graft and patients in Group 2 were completely de-aired with the pump off and the 
pump was only activated after removing the clamp.  
 
Results 
 
There were 45 patients in Group 1 (“clamp on”) and 33 patients in Group 2 (“clamp 
off”). Five patients had PT in Group 1 but none in Group 2 (p=0.07). Average LDH 
levels in the early postoperative period were similar (404±168 IU/L vs 425±267 
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IU/L; p=0.71). However, average LDH levels in the late postoperative period were 
significantly higher in Group 1 (388±214 IU/L vs 313±73 IU/L; p=0.045).   
 
Conclusion 
 
De-airing a running HMII with the outflow graft clamped increases LDH levels, 
suggesting that the bearings may act as a nidus for early thrombus formation 
caused by the lack of heat dissipation. Delaying pump activation until removal of 
the clamp on the outflow graft may affect the incidence of PT after HMII 
implantation. This may have potential importance in any VAD where there are 
mechanical bearings or other areas susceptible to heat generation. 
 
Keywords: HeartMate II, LVAD, thrombosis 
 
Introduction 
Left ventricular assist devices (LVADs) have transformed the manner in which 
patients with end-stage cardiomyopathy are managed. However, their use is not 
without risk. One particularly troublesome event is pump thrombosis which can 
manifest with embolization, recurrent heart failure or hemolysis. Pump thrombosis 
is relatively uncommon, with a rate of 2 - 4 % seen in the HeartMate II (HMII) 
bridge to transplantation and destination therapy trials [1, 2]. Recently, there has 
been increased attention to the issue of pump thrombosis, which was highlighted 
in the article by Starling et al. [3]. This demonstrated a pump thrombosis rate of 
8.4% over a period of 3 months in three centers. Multiple factors have been 
identified as potential risk factors for thrombosis of a left ventricular assist device 
(LVAD), including device-specific factors, patient-related factors, surgical 
implantation techniques, and post-operative management.  
In response to the article by Starling et al., we reevaluated all aspects of the 
management of patients undergoing LVAD implantation at our hospital for changes 
in patient management that could explain a potential rise in the rate of pump 
thrombosis. The only significant change identified in surgical technique, pump 
management or post-operative care was the method of pump de-airing prior to 
separation from bypass. Beginning in 2007, one author (JE) would routinely de-air 
prior to powering the pump, and the pump was only activated after de-airing was 
complete and the outflow graft was unclamped. As more pumps were implanted 
and discussions amongst clinicians allowed for cross-fertilization of ideas and 
techniques, the de-airing method was changed such that the pump was activated 
with the clamp across the outflow graft with a de-airing hole in the graft. This could 
speed the de-airing process and possibly decrease the potential for air 
embolization. This technique was adopted and used on all HMII patients without 
apparent short-term consequences beginning approximately in 2010. With the 
reports of increased pump thrombosis, the concern developed that this method of 
de-airing was a potential source for pump thrombosis due to heat generation on 
the inflow and outflow bearings when the pump was spinning in a pool of relatively 
stagnant blood, with subsequent protein denaturation and deposition on the 
bearings. As such, the de-airing method was changed back such that the HMII 
LVAD was never activated until de-airing was completed and the clamp across the 
outflow graft was removed. 
 
The VAD Journal: https://doi.org/10.13023/vad.2018.11 Page 3 of 11 
 
The VAD Journal: The journal of mechanical assisted circulation and heart failure 
Over the past several years, it has become apparent that elevations in lactate 
dehydrogenase (LDH) are an early marker of thrombosis, and as such, LDH is 
typically followed routinely in patients on LVAD support [4]. Even in the absence of 
other signs of potential pump thrombosis (hemolysis, pump power elevations, 
embolic events), a rise in LDH may lead to additional testing or a change in the 
anticoagulation regimen for a given patient.  
The aim of this study was to compare two de-airing methods and evaluate the 
impact on the incidence of pump thrombosis and LDH levels.  
Methods 
Patients 
All patients who underwent primary LVAD implantation with HeartMate II (Abbott 
Laboratories, Illinois, USA) by a single surgeon at a single institution from 
November 2012 to February 2016 were enrolled in the study. The method to de-air 
the pump was switched between March 2014 and May 2014. Data was collected 
retrospectively reviewing medical charts, which was approved by the institutional 
review board. Patients were separated into two groups depending on the timing of 
removal of the vascular clamp from the outflow graft. Patients in Group 1 
underwent de-airing by turning the pump on with the vascular clamp on the outflow 
graft and patients in Group 2 were completely de-aired with the pump off and 
activating the pump only after removing the clamp. 
Surgical procedure and anticoagulation management 
The only difference in surgical procedures between two groups was the timing of 
vascular clamp removal from the outflow graft. In the typical case, sternotomy is 
performed, followed by creation of the LVAD pocket and tunneling of the driveline. 
Heparin is then given. After cannulation, the outflow graft anastomosis is 
completed with a side-biting vascular clamp. The patient is then placed on bypass 
support. The inflow cannula connector is placed using a “cut-then-sew” technique. 
The LVAD inflow cannula is secured and actively vented. Once de-airing seems to 
be complete, the LVAD is connected to outflow graft and the LVAD and left 
ventricle are further de-aired through a 20-gauge hole in the outflow graft between 
the pump and the clamp on the outflow graft, using transesophageal 
echocardiography to assess the completeness of de-airing. In Group 1, this was 
performed with the pump on. In Group 2, the pump was off. The patient is weaned 
from bypass support while further de-airing occurs with a pressurized left ventricle. 
The clamp is then removed after making sure there was no air bubbles coming 
through the 20-gauge hole. In Group 2, the pump is activated at this point. In both 
groups, pump speeds are increased as tolerated. Protamine is given to reverse the 
heparin. Blood products are only administered for significant anemia, or 
coagulopathy with bleeding. Activated coagulation factors were avoided in all 
patients. The LVAD is secured into the pocket. Low pump speeds were avoided 
whenever possible. All implantation recommendations concerning pump pocket 
size and location, inflow cannula positioning and pump anchoring (PREVENT 
surgical recommendations) were followed in both groups [5] 
Heparin bridging was routinely used, and typically started on the first post-
operative day unless bleeding was present. Warfarin was started when the patient 
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was tolerating an oral diet, and adjusted for an International Normalized Ratio 
(INR) of 1.8-2.2. Aspirin 325 mg was administered daily once tolerating an oral 
diet. The INR and/or aspirin dose were decreased if there was GI bleeding. 
Additional antiplatelet agents were added or the INR goal increased if there was 
an unexpected significant rise in LDH, or worrisome elevations in pump power. A 
single person (JE) was involved in the decisions to change anticoagulation 
regimens in all patients. 
Study design 
The incidence of pump thrombosis within 3 months after implantation was 
compared between two groups. LDH levels were averaged over postoperative day 
(POD) 1 to 1 month (30 days) for the early postoperative period and 1 month to 3 
months (31 to 90 days) for the late postoperative period. These average LDH 
levels were compared between two groups. Primary outcome was pump 
thrombosis requiring replacement of the LVAD pump. Secondary outcome was 
bleeding or thromboembolic complication.  
Pump position was assessed by the criteria described by Adamson et al [6] and 
validated in the PREVENT Trial substudy on pump position [7]. Extreme pump 
position was defined as the following: 
a. Pocket depth ≤ 8 cm or ≥ 19 cm, or 
b. Inflow cannula angle relative to pump ≤ 46°, or 
c. Inflow cannula angle relative to vertical ≤ 0° or ≥ 39° 
Angles were measured on the scout image of the post-operative CT scan (if 
available) or on a chest radiograph that showed the entire body of the pump. 
Statistical analysis 
Continuous variables were expressed as mean ± standard deviation and 
compared with Student’s t-test.  Categorical variables were evaluated by chi-
square test or Fisher’s exact test as appropriate.  P values of less than 0.05 were 
deemed statistically significant.  Statistical analysis was performed using the R 
statistical software package version 3.2.2 (R foundation, Vienna, Austria). 
  
Results 
 
There were 45 patients in Group 1 (the pump started with the clamp on) and 33 
patients in Group 2 (the pump started with the clamp off). Table 1 shows baseline 
characteristics of the patients. Ischemic cardiomyopathy was significantly more 
common in Group 1 (p=0.015). The patients in Group 1 received significantly more 
intraoperative blood transfusions (3.0±3.1 versus 0.8±1.3, p<0.0001). All other 
factors including liver function, anticoagulation/antiplatelet and pump speed were 
not significantly different. None of the patients had perioperative issues suspected 
to be caused by air embolization.  
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Table 1: Characteristics of patients whose LVAD was started with the clamp on or off 
 Clamp ON (Group 1) 
 
Clamp OFF (Group 2) P value 
Number 45 33  
Age (years) 60.9±10.2 57.3±10.4 0.14 
Male 36 (84%) 24 (73%) 0.27 
Height (cm) 177±9 179±11 0.52 
Weight (kg) 189±39 200±50 0.29 
BMI 27.2±4.9 28.2±6.1 0.42 
Ischemic cardiomyopathy 21 (47%) 6 (19%) 0.015† 
INTERMACS 2.8±0.4 2.7±0.5 0.42 
Atrial fibrillation 20 (44%) 9 (27%) 0.16 
Hypertension 35 (78%) 21 (67%) 0.21 
Diabetes 20 (44%) 11 (33%) 0.36 
Deep vein thrombosis  0 (0%) 3 (9%) 0.18 
Cerebrovascular disease 5 (11%) 6 (18%) 0.51 
GFR (units) 50.2±10.7 52.6±10.6 0.34 
Total bilirubin (mg/dL) 0.94±1.03 0.97±0.83 0.88 
AST (IU/L) 39.8±42.9 32.5±33.5 0.42 
LDH (IU/L) 274±97 340±365 0.36 
Redo operation 10 (22%) 6 (19%) 0.78 
IABP 6 (13%) 4 (12%) 0.99 
ECMO 2 (4%) 2 (6%) 0.99 
TVR 7 (16%) 3 (9%) 0.51 
AVR 5 (11%) 0 (0%) 0.07 
MAP (discharge) (mmHg) 83.7±9.8 86.8±8.5 0.17 
Antiplatelet≥2 7 (16%) 5 (15%) 0.99 
Bridged w/ heparin 41 (91%) 33 (100%) 0.13 
Pump speed (ICU) 8933±267 8903±312 0.65 
Pump speed (discharge) 9118±253 9232±244 0.06 
Pump speed (30 day) 9123±249 9219±240 0.10 
INR (discharge) 2.26±0.57 2.29±0.60 0.88 
INR (30 day) 2.13±0.66 2.16±0.79 0.87 
PRBC (OR) 3.0±3.1 0.8±1.3 <0.0001† 
PRBC (postop) 4.9±5.8 4.0±5.9 0.5 
BMI: body mass index; GFR: glomerular filtration ratio; AST: Aspartate transaminase; LDH: 
lactate dehydrogenase; IABP: intraaortic balloon pump; ECMO: extracorporeal membrane 
oxygenation; TVR: tricuspid valve repair; AVR: aortic valve repair/replacement; MAP: mean 
arterial pressure; PRBC: packed red blood cells; †: statistically significant 
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Table 2 shows the outcome of the patients. There were five patients who required 
pump replacement because of pump thrombosis in Group 1. Four of them 
occurred within 3 months after initial implantation and required pump replacement. 
The last case was delayed thrombosis and resulted in a large stroke and the 
subsequent death of the patient. No patient in Group 2 had pump thrombosis. The 
difference in the incidence of pump thrombosis was not statistically significant 
(p=0.07). Average LDH levels in the early postoperative period (postoperative day 
1 to 30) were 404±168 in group 1 and 425±267 in group 2 (p=0.712). However, 
average LDH levels in the late postoperative period (postoperative day 31 to 90) 
were significantly higher in Group 1 (388±214 IU/L vs 313±73 IU/L; p=0.045) 
(Figure 1).   
Table 2. Outcomes 
 Clamp ON Clamp OFF P value 
Early LDH (IU/L) 404±168 425±267 0.71 
Late LDH (IU/L) 388±214 313±73 0.045† 
Pump thrombosis 5 0 0.07 
 
Early LDH: postoperative day 1 to 30; Late LDH: postoperative day 31 to 90 
LDH: lactated dehydrogenase 
†: statistically significant 
 
 
 
Figure 1. Starting the pump with a clamp ON/OFF on the outflow graft and 
LDH levels 
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Extreme pump position was present in 12/45 (27%) of patients de-aired with the 
pump on and in 12/33 (36%) of patients de-aired with the pump off and was almost 
exclusively due to a shallow pocket (< 8cm) (9/45 with pump on and 11/33 in pump 
off). Three patients in Group 1 (pump on) had an inflow cannula angle relative to 
vertical with an angle ≤ 0°. In Group 2 (pump off), two patients had an angle ≥ 
39° (one patient in this group also had a shallow pump pocket). Patients with 
extreme pump position were distributed throughout the study, negating the 
possibility of a learning curve. Table 3 shows the average values for pump position 
for each group.  Among the five patients with pump thrombosis, three had a 
normal pump position, one had a shallow pocket (68 mm) and one had an inflow 
cannula -7° relative to vertical. Even though three of the parameters had a p-value 
≤ 0.05, two of these parameters (depth of pump pocket and pump angle relative 
to the spine) favored Group 1. 
Table 3: Pump placement characteristics 
 De-air with pump on De-air with pump off P value 
Pocket depth (mm) 99.3[91.8, 128.9] 91.7 [76.9, 117.4] 0.05 
Outflow cannula angle 
related to pump body 
(°) 
103.0 [99.0, 107.0] 107.0 [100.0, 113.0] 0.08 
Pump angle relative to 
spine (°) 
88.0 [84.0, 97.0] 
(mean 90.8) 
88.0 [78.0, 92.0] 
(mean 85.5) 
< 0.01 
Inflow cannula angle 
relative to pump body 
(°) 
66.0 [64.0, 75.0] 70.0 [64.0, 75.0] 0.01 
Inflow cannula angle 
relative to vertical 
parallel to spine (°) 
20.0 [14.0, 31.0] 20.0 [18.0, 28.0] 0.11 
Data is presented as median values [IQR] 
There was no difference between preoperative ejection fraction, post-operative 
ejection fraction, preoperative left ventricular end-diastolic diameter (LVIDd) or 
post-operative LVIDd between the groups. Overall, there was an increase in the 
ejection fraction of 5 percentage points after implantation of the LVAD, and a 
decreased in the LVIDd of 1 cm, as would be expected with unloading of the 
hearts. 
Discussion 
Pump thrombosis is a serious complication of LVAD support, and usually requires 
pump replacement or urgent heart transplantation. It is associated with a high 
incidence of other complications such as embolization and mortality. After an initial 
period of relatively low rates of pump thrombosis, there was a perceived increase 
at some centers. This led to a national discussion and further investigation into the 
question and possible causes. 
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One possibility for this increase is that the bearings act of the HMII as a nidus for 
thrombus deposition either during the implantation procedure, or shortly thereafter. 
While there may be numerous potential causes for this deposition, one concern is 
that it may occur during the de-airing process of the LVAD. When de-airing the 
LVAD with the pump on and a clamp across the outflow graft, there is no flow 
through the pump, and a diminished capacity to dissipate the heat generated by 
the pump motor and by the friction of the bearings at either end of the rotor. In a 
study looking at a ‘zero-flow’ situation in short-term centrifugal pumps, a 
temperature change of approximately 5⁰C was seen after only 90 seconds [8]. 
Heat generation in a pump is higher than normal when there is increased load on 
the pump [9], a situation that can easily occur with outflow occlusion. The heat 
generation described in these studies likely underestimates the maximal heat seen 
in the HeartMate II under a ‘zero-flow’ scenario, as the temperature at the contact 
point between the two bearings has not been measured, and is likely to be 
significantly higher than the temperature of the blood itself. Heat dissipation occurs 
primarily through two mechanisms – thermal radiation into the surrounding tissues 
and removal as blood flows through the device [9]. When there is no blood flow 
through the pump, one of the main mechanisms of heat removal is nullified, 
leading to increased temperatures within the body of the LVAD in general, and at 
the point of the bearings specifically [10]. Protein degradation can begin to occur at 
temperatures between 43-45⁰C [11], temperatures easily obtainable under the de-
airing scenario described. This heat generation is associated with a drop in platelet 
count, likely due to adhesion of the platelets to the heated surface, and to a 66% 
increase in the amount of material adherent to the heated surfaces [10]. Heat 
generation is felt to be one of the factors involved in initiating the sequence of fibrin 
deposition that ultimately leads to local thrombus formation and pump thrombosis 
[12]. 
In our current study, the patients whose pump was started with a clamp on (Group 
1) tended to have higher incidence of pump thrombosis, although it was not 
statistically significant. The reason it did not reach statistical significance is likely to 
be relatively small patient population and rarity of the event. They also had 
significantly higher LDH levels in the late postoperative period (31 to 90 days after 
implantation). It is possible that the timing of clamp removal affected the incidence 
of pump thrombosis. Furthermore, that patients in Group 2 did not have a higher 
incidence of suspected air embolization including stroke or right ventricular failure 
from incomplete de-airing. Therefore, it would be prudent to say we should not run 
the pump with the outflow graft occluded. The reason that there was no difference 
in early postoperative LDH is probably because there were other factors like tissue 
injury, liver damage or transfusions that could affect LDH levels in the early 
postoperative period.  
There were a few events that occurred between approval of the HeartMate II pump 
and the perceived rise in the rate of pump thrombosis, each with the potential to 
contribute to this increase. Data demonstrated that patients on HeartMate II 
support could be managed without heparin bridging [13].  There was an increased 
recognition of LDH as an early marker of pump thrombosis [14]. There were 
modifications in the HeartMate II technology, with the introduction of a modified, 
sealed outflow graft. In addition, there was the rise of competing technology, such 
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as the HeartWare HVAD. Each could have led to the rise in pump thrombosis in 
different ways. 
In the HeartMate II trials, bridging with heparin was recommended. Subsequently, 
Slaughter et al published data suggesting that heparin bridging was not necessary 
in the HMII as there was an increased risk of bleeding associated with bridging 
and no appreciable increase in embolic or thrombotic events in the absence of 
bridging [13]. While it is difficult to quantitate, there seemed to be a change in the 
practice at many VAD centers in relation to heparin bridging following the 
publication of this data, although our policy on heparin did not change over that 
time period. 
LDH has become an accepted method for monitoring the amount of hemolysis 
produced by an LVAD. As pump thrombosis is usually associated with an increase 
in the LDH, it has become a proxy for early pump thrombosis such that many 
centers will increase the frequency of monitoring, increase anticoagulation or do 
additional testing if there is a significant rise in LDH. The increased use of LDH as 
a marker seems to have occurred around 2012-3 when there were increased 
numbers of presentations at national meetings. More attention to rises in LDH may 
have led to the increased recognition and diagnosis of probable pump thrombosis 
where it may not have been otherwise suspected. 
The timing of the spike in pump thrombosis published by Starling et al. [3] 
coincided with the release of the gelatin-impregnated outflow graft on the 
HeartMate II, and was felt by some to be the source of the increased rate of 
thrombosis. However, a study that analyzed the rate of suspected cases of pump 
thrombosis nationwide comparing gelatin-impregnated to non-impregnated outflow 
grafts found that there were more queries regarding potential pump issues that 
occurred over a relatively short period of time and occurred in pumps both with 
and without the modified outflow grafts [15]. 
The final factor that comes into play is the rise of competing technologies. The 
HeartWare HVAD system was approved by the FDA for use in patients awaiting 
transplantation in late 2012. It is possible that as clinicians gained experience with 
other devices such as the HVAD, they altered their techniques and management 
of patients with the HeartMate II. With the lack of bearings and contact points, de-
airing of the HVAD (and later with the HeartMate 3) is theoretically not likely to 
generate as much heat and thus not serve as a nidus for protein deposition that 
could be seen with the HeartMate II device.  
It is clear that there is no single cause of pump thrombosis, and there is likely a 
rate of thrombosis that is inherent to each system which cannot be eliminated. It 
seems unlikely that the perceived spike in pump thrombosis was related to the 
modification in the HeartMate II outflow graft. It most likely resulted from a change 
in patient selection, implantation technique, anticoagulation management, and/or 
recognition of thrombosis events. We propose that running the HMII LVAD pump 
with the outflow graft occluded was one of the factors that may have caused some 
cases of pump thrombosis.  
This study has several limitations. First and foremost, the patients were divided 
into two groups that were implanted during two different periods of time. It is 
possible that there were other changes in patient selection or management that 
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occurred over this time that were not recognized. Secondly, the conclusions are 
based primarily on LDH values and not on actual episodes of pump thrombosis. 
This was done since thrombosis is an infrequent event. However, there was a 
trend towards a higher rate of thrombosis in the patients who underwent 
implantation in Group 1, but it did not reach statistical significance. Finally, without 
knowledge of how many surgeons de-air with each technique and their personal 
rates of pump thrombosis, it is difficult to make generalizations in the applicability 
of the data to other programs.  
In conclusion, running the HeartMate II LVAD pump with the outflow graft clamped 
may increase the incidence of pump thrombosis. Release of the outflow graft 
clamp before starting the pump may reduce this risk. While the approval of new 
bearingless pumps such as the HeartMate 3 will likely lead to decreased usage of 
the HeartMate II, the lessons learned from this study may be applicable to future 
pumps that have bearings where heat dissipation is important. 
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